Surface Markers of Cancer Stem-like Cells of Ovarian Cancer and Their Clinical Relevance

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2018 Apr 10

PMID 29628794

Citations 30

Authors

Aleksandra Klemba

J Karolina Purzycka-Olewiecka

Gabriel Wcislo

Anna M Czarnecka

Slawomir Lewicki

Bogdan Lesyng

Cezary Szczylik

Claudine Kieda

Affiliations

Soon will be listed here.

Abstract

Cancer stem-like cells (CSLCs) are defined as cancer cells with stem cell characteristics. Although CSLCs constitute no more than a few percent of the tumor mass, they play important roles in cancer chemo-resistance, metastasis and disease recurrence. Ovarian cancer (OC) is considered the most aggressive gynecological malignancy in which the role of CSLCs is of major significance, although it remains to be specified. The studies describing ovarian CSLC phenotype vary in the definition of the molecular pattern of expression of the main markers such as CD133, CD44, CD117, and CD24. Stem-like features of OC have been shown to correlate with the clinical course of the disease and permit diagnosis, prognosis and treatment outcome to be improved. Identification of CSLC markers could provide hallmarks which, related to the chemo-resistance of the disease, will facilitate treatment selection. This review describes recent advances in research on stem-like cell status in OC, mainly focusing on surface markers of CSLCs and their clinical relevance.

Citing Articles

Knocking down RAD51AP1 enhances chemosensitivity by inhibiting the self-renewal of CD133 positive ovarian cancer stem-like cells.

Zeng S, Yan Z, Ren Q, Lin L, Chen Z Discov Oncol. 2024; 15(1):410.

PMID: 39235706 PMC: 11377390. DOI: 10.1007/s12672-024-01258-9.

Cancer Stem Cells (CD44/CD24), RAD6, DDB2 Immunohistochemistry Expression and IHC-UNEDO Scoring System As Predictor of Ovarian Cancer Chemoresistance.

Sihombing U, Andrijono A, Purwoto G, Gandamihardja S, Harahap A, Rustamadji P J Obstet Gynaecol India. 2024; 74(3):236-242.

PMID: 38974750 PMC: 11224164. DOI: 10.1007/s13224-023-01829-w.

Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis.

Wang G, Liu X, You Y, Chen S, Chang X, Yang Q J Ovarian Res. 2024; 17(1):58.

PMID: 38481252 PMC: 10935861. DOI: 10.1186/s13048-023-01326-8.

Surprising magic of CD24 beyond cancer.

Wang H, Shi P, Shi X, Lv Y, Xie H, Zhao H Front Immunol. 2024; 14:1334922.

PMID: 38313430 PMC: 10834733. DOI: 10.3389/fimmu.2023.1334922.

The Role of Cancer Stem Cell Markers in Ovarian Cancer.

Fraszczak K, Barczynski B Cancers (Basel). 2024; 16(1).

PMID: 38201468 PMC: 10778113. DOI: 10.3390/cancers16010040.

References

Nakamura K, Terai Y, Tanabe A, Ono Y, Hayashi M, Maeda K . CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol Rep. 2017; 37(6):3189-3200. PMC: 5442399. DOI: 10.3892/or.2017.5583. View

Witt A, Lee C, Lee T, Azzam D, Wang B, Caslini C . Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2016; 36(12):1707-1720. PMC: 5364039. DOI: 10.1038/onc.2016.337. View

Li Z, Block M, Vierkant R, Fogarty Z, Winham S, Visscher D . The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumour Biol. 2016; 37(10):13279-13286. PMC: 5097682. DOI: 10.1007/s13277-016-5163-2. View

Shah V, Taratula O, Garbuzenko O, Taratula O, Rodriguez-Rodriguez L, Minko T . Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013; 19(22):6193-204. PMC: 3846837. DOI: 10.1158/1078-0432.CCR-13-1536. View

Alvero A, Fu H, Holmberg J, Visintin I, Mor L, Marquina C . Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells. 2009; 27(10):2405-13. PMC: 2783765. DOI: 10.1002/stem.191. View

Skubitz A, Taras E, Boylan K, Waldron N, Oh S, Panoskaltsis-Mortari A . Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 2013; 130(3):579-87. PMC: 3906852. DOI: 10.1016/j.ygyno.2013.05.027. View

Wintzell M, Lofstedt L, Johansson J, Pedersen A, Fuxe J, Shoshan M . Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther. 2012; 13(14):1454-62. PMC: 3542237. DOI: 10.4161/cbt.22007. View

Choi Y, Park J, Han J, Kim E, Jae-Wook O, Lee S . Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells. Int J Mol Sci. 2016; 17(12). PMC: 5187877. DOI: 10.3390/ijms17122077. View

Gao M, Choi Y, Kang S, Youn J, Cho N . CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010; 29(18):2672-80. DOI: 10.1038/onc.2010.35. View

10.

Zhang J, Chang B, Liu J . CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Hum Pathol. 2013; 44(9):1882-9. PMC: 3752324. DOI: 10.1016/j.humpath.2013.02.016. View

11.

Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A . Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2007; 18(3):506-14. DOI: 10.1111/j.1525-1438.2007.01056.x. View

12.

Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D . Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol. 2011; 91(2):596-602. DOI: 10.1016/j.yexmp.2011.06.005. View

13.

Shtivelman E, Bishop J . Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol. 1991; 11(11):5446-53. PMC: 361913. DOI: 10.1128/mcb.11.11.5446-5453.1991. View

14.

Stewart J, Shaw P, Gedye C, Bernardini M, Neel B, Ailles L . Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 2011; 108(16):6468-73. PMC: 3081039. DOI: 10.1073/pnas.1005529108. View

15.

Alvero A, Montagna M, Holmberg J, Craveiro V, Brown D, Mor G . Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 2011; 10(8):1385-93. PMC: 3703662. DOI: 10.1158/1535-7163.MCT-11-0023. View

16.

Min K, So K, Ouh Y, Hong J, Lee J . The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers. J Ovarian Res. 2012; 5(1):28. PMC: 3489563. DOI: 10.1186/1757-2215-5-28. View

17.

Zhang S, Balch C, Chan M, Lai H, Matei D, Schilder J . Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-20. PMC: 2553722. DOI: 10.1158/0008-5472.CAN-08-0364. View

18.

Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T . High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci. 2012; 20(5):605-15. PMC: 3635069. DOI: 10.1177/1933719112461183. View

19.

Permuth-Wey J, Sellers T . Epidemiology of ovarian cancer. Methods Mol Biol. 2008; 472:413-37. DOI: 10.1007/978-1-60327-492-0_20. View

20.

Zhang J, Guo X, Chang D, Rosen D, Mercado-Uribe I, Liu J . CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2011; 25(3):456-64. PMC: 3855345. DOI: 10.1038/modpathol.2011.170. View